DnB Asset Management
ACAD icon

DnB Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

DnB Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$585K Buy
23,123
+4,600
+25% +$101K ﹤0.01% 739
2026
Q1 		$412K Buy
18,523
+3,821
+26% +$91.3K ﹤0.01% 831
2025
Q4 		$393K Buy
14,702
+1,525
+12% +$36.4K ﹤0.01% 687
2025
Q3 		$281K Buy
13,177
+2,258
+21% +$53.4K ﹤0.01% 697
2025
Q2 		$236K Sell
10,919
-4,692
-30% -$87.2K ﹤0.01% 688
2025
Q1 		$259K Buy
15,611
+1,409
+10% +$25.6K ﹤0.01% 699
2024
Q4 		$261K Buy
14,202
+3,964
+39% +$64K ﹤0.01% 696
2024
Q3 		$157K Buy
10,238
+113
+1% +$1.89K ﹤0.01% 698
2024
Q2 		$165K Buy
+10,125
New +$163K ﹤0.01% 697
2023
Q3 		– Sell
-12,141
Closed -$291K – 659
2023
Q2 		$291K Buy
+12,141
New +$270K ﹤0.01% 650
2022
Q3 		– Sell
-46,171
Closed -$651K – 647
2022
Q2 		$651K Sell
46,171
-21,471
-32% -$401K ﹤0.01% 617
2022
Q1 		$1.64M Sell
67,642
-14,440
-18% -$349K 0.01% 570
2021
Q4 		$1.92M Sell
82,082
-8,758
-10% -$176K 0.01% 569
2021
Q3 		$1.51M Sell
90,840
-2,119
-2% -$40.8K 0.01% 575
2021
Q2 		$2.27M Buy
92,959
+483
+0.5% +$10.9K 0.02% 520
2021
Q1 		$2.39M Buy
92,476
+37,378
+68% +$1.65M 0.02% 500
2020
Q4 		$2.95M Buy
55,098
+32,556
+144% +$1.62M 0.03% 381
2020
Q3 		$930K Buy
+22,542
New +$973K 0.01% 531

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

DnB Asset Management's ACAD Position: Q2 2026 in Review

DnB Asset Management increased its Acadia Pharmaceuticals (ACAD) stake by 25% in Q2 2026, buying an estimated $101K and bringing the position to 23,123 shares worth $585K. The position accounts for ﹤0.01% of the portfolio, ranked #739.

DnB Asset Management first reported a position in ACAD in Q3 2020 and has held it in 18 quarters since. The position peaked at $2.95M in Q4 2020. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • DnB Asset Management held 23,123 shares of Acadia Pharmaceuticals worth $585K as of Q2 2026.
  • DnB Asset Management bought 4,600 Acadia Pharmaceuticals shares in Q2 2026, an estimated $101K.
  • Acadia Pharmaceuticals made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #739 holding.
  • DnB Asset Management first reported a position in Acadia Pharmaceuticals in Q3 2020 and has held it in 18 quarters since.
  • DnB Asset Management's Acadia Pharmaceuticals position peaked at $2.95M in Q4 2020.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.